The effects of ¿9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis

J. M. Jamontt, A. Molleman, Roger Guy Pertwee, M. E. Parsons

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background and purpose: Cannabis is taken as self-medication by patients with inflammatory bowel disease for symptomatic relief. Cannabinoid receptor agonists decrease inflammation in animal models of colitis, but their effects on the disturbed motility is not known. (-)-Cannabidiol (CBD) has been shown to interact with ¿9-tetrahydrocannabinol (THC) in behavioural studies, but it remains to be established if these cannabinoids interact in vivo in inflammatory disorders. Therefore the effects of CBD and THC alone and in combination were investigated in a model of colitis.


Experimental approach: The 2,4,6-trinitrobenzene sulphonic acid (TNBS) model of acute colitis in rats was used to assess damage, inflammation (myeloperoxidase activity) and in vitro colonic motility. Sulphasalazine was used as an active control drug.


Key results: Sulphasalazine, THC and CBD proved beneficial in this model of colitis with the dose–response relationship for the phytocannabinoids showing a bell-shaped pattern on the majority of parameters (optimal THC and CBD dose, 10mg·kg-1). THC was the most effective drug. The effects of these phytocannabinoids were additive, and CBD increased some effects of an ineffective THC dose to the level of an effective one. THC alone and in combination with CBD protected cholinergic nerves whereas sulphasalazine did not.


Conclusions and implications: In this model of colitis, THC and CBD not only reduced inflammation but also lowered the occurrence of functional disturbances. Moreover the combination of CBD and THC could be beneficial therapeutically, via additive or potentiating effects.

Original languageEnglish
Pages (from-to)712-723
Number of pages12
JournalBritish Journal of Pharmacology
Volume160
Issue number3
Early online date1 Apr 2010
DOIs
Publication statusPublished - Jun 2010

Keywords

  • delta 9-tetrahydrocannabinol
  • cannabidiol
  • cannabinoids
  • sulphasalazine
  • colitis
  • inflammation
  • motility
  • inflammatory bowel disease
  • hapten-induced colitis
  • TNBS-induced colitis
  • bowel-disease
  • pharmacological interaction
  • colonic inflammation
  • cytokine production
  • plant cannabinoids
  • mice
  • model
  • delta(9)-tetrahydrocannabinol
  • ¿9-tetrahydrocannabinol

Cite this